Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Advisory Services Network LLC

Advisory Services Network LLC boosted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 59.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 60,459 shares of the company's stock after purchasing an additional 22,648 shares during the period. Advisory Services Network LLC owned about 0.16% of Tarsus Pharmaceuticals worth $3,348,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of TARS. Crowley Wealth Management Inc. acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth approximately $25,000. R Squared Ltd bought a new position in Tarsus Pharmaceuticals during the fourth quarter worth $53,000. HighTower Advisors LLC acquired a new position in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $207,000. Victory Capital Management Inc. acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter worth $223,000. Finally, Oppenheimer & Co. Inc. acquired a new position in Tarsus Pharmaceuticals during the 4th quarter valued at about $227,000. Institutional investors and hedge funds own 90.01% of the company's stock.

Insider Activity

In other news, General Counsel Bryan Wahl sold 3,084 shares of the firm's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $154,539.24. Following the completion of the transaction, the general counsel now owns 51,712 shares of the company's stock, valued at approximately $2,591,288.32. This trade represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Dianne C. Whitfield sold 2,315 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $107,161.35. Following the completion of the transaction, the insider now directly owns 50,751 shares in the company, valued at $2,349,263.79. This trade represents a 4.36 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,542 shares of company stock worth $1,581,173. Corporate insiders own 8.25% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Oppenheimer lifted their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Guggenheim reaffirmed a "buy" rating and issued a $78.00 price target (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. HC Wainwright reiterated a "buy" rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Jefferies Financial Group increased their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Finally, Barclays dropped their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $63.67.

Tarsus Pharmaceuticals Trading Down 0.9 %

Shares of NASDAQ TARS traded down $0.44 during midday trading on Wednesday, reaching $48.68. The company had a trading volume of 91,308 shares, compared to its average volume of 679,459. The stock has a market cap of $1.87 billion, a PE ratio of -12.78 and a beta of 0.94. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.28. The firm's fifty day moving average price is $47.92 and its 200-day moving average price is $47.44. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.08. The business had revenue of $66.41 million for the quarter, compared to analysts' expectations of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. On average, equities research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.